{
  "slug": "glycine",
  "name": "Glycine",
  "alternate_names": [
    "Glycine",
    "Aminoacetic acid",
    "L-Glycine",
    "Gly"
  ],
  "mechanism": [
    "Inhibitory neurotransmitter + NMDA co-agonist (linked to core-body-temperature drop and sleep onset in research)",
    "Glutathione synthesis precursor amino acid",
    "Collagen synthesis substrate (~1/3 of collagen residues)"
  ],
  "target": [
    "NMDA receptor (GRIN subunits)",
    "Glutathione pool",
    "Collagen substrate pool"
  ],
  "use_case": [
    "sleep quality / relaxation (research-context)",
    "glutathione / antioxidant support (research-context)",
    "collagen amino-acid support (research-context)"
  ],
  "body_system": [
    "SLEEP",
    "NEURO",
    "MITO",
    "SKIN"
  ],
  "evidence_tier": "C",
  "evidence_anchor_pmid_count": 3,
  "dosage_range": "3 g/day before bed in sleep research; 3-5 g/day in metabolic studies; GlyNAC aging research used ~100 mg/kg/day glycine combined with NAC. US market median ~1000 mg/day. Educational reference, not a dosing recommendation.",
  "safety_notes": "Well tolerated at 3-5 g/day in human studies; schizophrenia research used up to 60 g/day without serious adverse events; no official upper limit. High doses over 10 g occasionally linked to mild GI discomfort or drowsiness. Caution with clozapine (possible reduced efficacy); inadequate pregnancy/lactation data. Educational, not medical advice.",
  "regulatory": {
    "fda": "GRAS by direct listing under 21 CFR 172.320 (amino acids added to foods); pre-1994 Old Dietary Ingredient under DSHEA; marketed as a dietary supplement with structure/function claims only",
    "efsa": "Authorized food-supplement amino acid under Directive 2002/46/EC Annex I; 0 glycine-specific authorized health claims (general structure/function language only)",
    "anvisa": "Permitted dietary-supplement amino-acid raw material (RDC 243/2018 / IN 28/2018); no glycine-specific Anexo V functional claim"
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/glycine/",
  "related_goal_slugs": [
    "cognitive-support",
    "longevity-stack"
  ],
  "related_lifestyle_slugs": [
    "high-stress"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}